| Size | Price | Stock | Qty |
|---|---|---|---|
| 10g |
|
||
| 25g |
|
||
| Other Sizes |
| Targets |
Fmoc-D-Cha-OH targets peptide synthesis applications and has been identified as an apoptotic DNase γ inhibitor that inhibits the release of HMGB1. The D-configuration provides stereochemical control for producing single-stereoisomer peptides. The cyclohexylalanine residue can modulate peptide hydrophobicity and conformation. The Fmoc group enables standard Fmoc-based SPPS.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
In vitro, Fmoc-D-Cha-OH (FDCO) has been identified as an apoptotic DNase γ inhibitor that inhibits the release of HMGB1. Amino acid derivatives have been used as ergogenic supplements, affecting the release of anabolic hormones and fuel availability. The compound can be used in cell culture to study apoptosis and HMGB1 release pathways. |
| ln Vivo |
In vivo, Fmoc-D-Cha-OH has been studied for its role as an apoptotic DNase γ inhibitor and HMGB1 release inhibitor. The D-configuration can provide resistance to proteolytic degradation. The compound may be used in animal studies to investigate apoptosis, inflammation, and HMGB1-mediated signaling pathways.
|
| Enzyme Assay |
In vitro enzyme/receptor binding protocols for Fmoc-D-Cha-OH involve studying its inhibition of apoptotic DNase γ activity. The compound is incubated with purified enzyme or in cell lysates, and DNase activity is measured using DNA degradation assays. Inhibition of HMGB1 release can be assessed by ELISA in cell culture supernatants. For peptide synthesis, standard SPPS protocols apply.
|
| Cell Assay |
Cell culture protocols for Fmoc-D-Cha-OH involve dissolving the compound in DMSO or appropriate buffers. Cells are treated with concentrations ranging from 0.1-100 µM for 24-72 hours. Effects on apoptosis, DNase activity, and HMGB1 release are assessed. Cell viability can be measured using MTT or other assays. The compound has solubility in DMSO of 90 mg/mL.
|
| Animal Protocol |
In vivo animal study protocols for Fmoc-D-Cha-OH involve administration via oral gavage or injection in appropriate vehicles. Dosing would be determined empirically. Studies may assess effects on apoptosis, inflammation, and HMGB1 levels in tissues. Blood and tissue samples are collected for analysis of compound distribution, HMGB1 levels, and apoptotic markers. Standard animal welfare protocols apply.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Fmoc-D-Cha-OH are characteristic of protected amino acid derivatives. The compound has a molecular weight of 393.48 g/mol, formula C₂₄H₂₇NO₄, and appears as a white to off-white powder. Solubility in DMSO is 90 mg/mL. Storage: powder at -20°C for 3 years. The Fmoc group is removed under basic conditions during peptide synthesis.
|
| Toxicity/Toxicokinetics |
Toxicological data for Fmoc-D-Cha-OH is limited. The compound is for research use only. Standard safety precautions should be observed. Acute toxicity is expected to be low. Store as powder at -20°C. Proper personal protective equipment should be worn when handling. No specific toxicity studies have been reported. It is not intended for human therapeutic use.
|
| References | |
| Additional Infomation |
Fmoc-D-Cha-OH (CAS#: 144701-25-7) is also known as Fmoc-D-cyclohexylalanine, Fmoc-3-cyclohexyl-D-alanine, and (R)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-cyclohexylpropanoic acid. Its molecular formula is C₂₄H₂₇NO₄ and molecular weight is 393.48 g/mol. It is an apoptotic DNase γ inhibitor that inhibits HMGB1 release and is used as a building block in SPPS. It has no approved therapeutic indications.
|
| Molecular Formula |
C24H27NO4
|
|---|---|
| Molecular Weight |
393.47548
|
| Exact Mass |
393.194
|
| CAS # |
144701-25-7
|
| PubChem CID |
978327
|
| Appearance |
White to off-white powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
610.5±38.0 °C at 760 mmHg
|
| Flash Point |
323.0±26.8 °C
|
| Vapour Pressure |
0.0±1.8 mmHg at 25°C
|
| Index of Refraction |
1.589
|
| LogP |
6.13
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
29
|
| Complexity |
551
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O=C(O)[C@H](NC(OCC1C2=CC=CC=C2C3=CC=CC=C31)=O)CC4CCCCC4
|
| InChi Key |
HIJAUEZBPWTKIV-JOCHJYFZSA-N
|
| InChi Code |
InChI=1S/C24H27NO4/c26-23(27)22(14-16-8-2-1-3-9-16)25-24(28)29-15-21-19-12-6-4-10-17(19)18-11-5-7-13-20(18)21/h4-7,10-13,16,21-22H,1-3,8-9,14-15H2,(H,25,28)(H,26,27)/t22-/m1/s1
|
| Chemical Name |
(2R)-3-cyclohexyl-2-(9H-fluoren-9-ylmethoxycarbonylamino)propanoic acid
|
| Synonyms |
(R)-2-((((9H-Fluoren-9-yl)methoxy)carbonyl)amino)-3-cyclohexylpropanoic acid; Fmoc-D-Cha-OH
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~254.14 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (6.35 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (6.35 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (6.35 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.5414 mL | 12.7071 mL | 25.4143 mL | |
| 5 mM | 0.5083 mL | 2.5414 mL | 5.0829 mL | |
| 10 mM | 0.2541 mL | 1.2707 mL | 2.5414 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
